Earnings Releases·Nov 2, 2026, 4:05 PM ET

Travere Therapeutics — Third Quarter 2026 Earnings Summary

U.S. net product sales surged 95% year-over-year to $220.2 million in Q3 2026, driven by a 120% increase in FILSPARI® revenue to $200.2 million, though the company reported a GAAP net loss of $52.3 million versus net income of $25.7 million in the prior year period.
The quarter included a significant $113.1 million in-process research and development expense related to the closing of the exclusive licensing agreement with Everest Medicines for civorebrutinib, alongside a 45% increase in SG&A expenses to $98.4 million.
Strategic leadership transition announced with Bradley L. Campbell set to succeed Eric Dube as President and CEO effective December 1, 2026, while Dube remains as executive advisor through February 2027.
Pipeline progress includes completed enrollment for the Phase 4 SPARLIGHT Study, anticipated top-line results for the pegtibatinase Phase 3 HARMONY Study in H2 2027, and an IND submission for civorebrutinib planned by year-end.
Balance sheet strength remains robust with $471.8 million in cash, equivalents, and marketable securities as of September 30, 2026, despite convertible debt increasing to $603.5 million from the end of 2025.